Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Isis discloses data from phase II trial in patients with hypertriglyceridemia and type 2 diabetes

May 5, 2014

Eli Lilly to begin a phase II study of LY-2944876 in type 2 diabetes

May 5, 2014

Advinus Therapeutics prepares novel DGAT1 inhibitors for diabetes and other disorders

May 2, 2014

Amicus Therapeutics reports data from phase III trial of migalastat

April 30, 2014

IMM-H007 reduces atherosclerotic plaque in mice and increases circulating HDL levels

April 30, 2014

European approval for BioMarin's Vimizim for Morquio A syndrome

April 29, 2014

Merck KGaA reports outcome of phase IIIb study of Kuvan

April 29, 2014

Cell Pouch device demonstrates continued biocompatibility in type 1 diabetes study

April 29, 2014

EMA approves canagliflozin and metformin combination

April 28, 2014

Hyperion Therapeutics to acquire Andromeda Biotech

April 28, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 9, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026